What’s Happening
Chatter
- Can anyone help me, how can i clean this cuvette?
- Looking to move from a CRC roll to a CRA.
- I already have an MBA, is it worth getting a masters in clinical research?
- College senior debating on whether to get a PhD or go straight into industry
- servier pharmaceuticals
- Novo Nordisk Interview – Final Round Advice?
- Something to look into:
- I feel like this sub needs a review of reconciliation vs. discretionary spending, and how those relate to research
- How much relocation bonus is typically offered?
- Important:- Want your help
- Anyone else personify the proteins they measure?
- It must feel so nice having financial support from your family
- PRGN-2012: Repeat-Dose Adenoviral IL‑12 for RRP – A Platform Breakthrough?
- Transitioning from Oil & Gas QC Tech to Pharma/Biotech QA
- PI Signatures
Charts
Research
Longboard Pharma and Bexisaserin
Longboard Pharma was acquired by H. Lundbeck A/S on Oct 14, 2024 at about $60 per share. The deal valued Longboard at roughly $2.6 billion dollars, which made it one of the highest returning biopharma stocks of the year. That acquisition price, if closed on, will deliver an 800% return for shareholders YTD at time of writing. Today we will take a closer look at this clinical stage pharma company, and its primary asset, bexicaserin.
…